On the contrary, patients who aged ≥ 60 years (OR: 0.68, 95% CI 0.57–0.83), having history of hypertension (OR: 0.82, 95% CI 0.67–0.98) and anemia (OR: 0.72, 95% CI 0.57–0.90) were less likely to use SGLT2 inhibitor; moreover, patients with eGFR < 30 ml/min/1.73 m2 were less likely to use an SGLT2i than eGFR between 30 and 59 ml/min/1.73 m2 (OR: 0.16, 95% CI 0.10–0.25) (Fig. 7). The gene discussed is SLC5A2; the disease is Hypertension.